Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam and Merck Amend, Consolidate RNAi Alliances

NEW YORK (GenomeWeb News) - Alnylam Pharmaceuticals has amended its two RNAi collaboration agreements with Merck and consolidated them into a single collaboration, Alnylam said today.
 
The amendments focus on the nine new therapeutic targets that Merck will name at a later date. These new programs are in addition to the existing collaboration on NOGO pathway for spinal cord injury treatments.
 
Under the revised terms, Alnylam will identify three of the nine new programs as joint development programs. Merck will co-fund and participate in the joint programs, providing Alnylam with accelerated R&D funding for its efforts.
 
Alnylam will have the right to co-promote RNAi therapeutic products developed in the joint programs in the US.
 
Merck will assume primary responsibility for the remaining six programs. Alnylam will receive milestone payments and royalties of over $120 million on products developed and commercialized from those programs.
 
Alnylam and Merck will not jointly advance their July 2004 Ocular Disease alliance, the company said. Alnylam will retain all rights to ALN-VEG01.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.